Executive record

Eric Venker, M.D., Pharm.D.

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:eric-venker-m-d-pharm-d-imvtVersion: public-0As of: 2026-09-30

Not yet claimed8 published Claims2 sources

Key Claims

Biography

Dr. Venker serves as Chief Executive Officer of Immunovant. His biography is referenced elsewhere in the filing under Series A Preferred Stock Directors.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2025 to end not publishedExecutive title: Chief Executive Officer · Organization not publishedIMVT DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. IMVT DEF 14A executive officers

    sec filing · Source published: Jul 9, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Executive Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. IMVT executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Immunovant Inc · Claim reviewed: May 15, 2026
    • Executive function: Enterprise Leadership (CEO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Executive Officer · Claim reviewed: May 15, 2026